🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

10 recruiting trials

for Oligoarthritis, Juvenile

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis NCT03773965Phase 378 sites📍 Rosario📍 SAN M. de Tucuman📍 Melbourne Eli Lilly and Company · Tests: Baricitinib An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis NCT06668181Phase 323 sites📍 Calgary📍 Montreal📍 Saskatoon UCB Biopharma SRL · Tests: Bimekizumab STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS NCT03728478Phase 31 site📍 Genova Istituto Giannina Gaslini · Tests: Etanercept, Methotrexate, Intra-articular corticosteroid injections A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis NCT05767047Phase 37 sites📍 Thessaloniki📍 Kfar Saba📍 Valencia Amgen · Tests: Apremilast Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis NCT04804553Phase 344 sites📍 Ghent📍 Liège📍 Merksem Amgen · Tests: Apremilast, Placebo A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants NCT06663332Phase 351 sites📍 Atlanta📍 Atlanta📍 Indianapolis Janssen Research & Development, LLC · Tests: Guselkumab A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab NCT06100744Phase 334 sites📍 Little Rock📍 Washington D.C.📍 Hollywood AbbVie · Tests: Adalimumab, Risankizumab Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry NCT02418442n/a82 sites📍 Birmingham📍 Phoenix📍 Los Angeles Duke University Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). NCT06751238Phase 111 sites📍 Loma Linda📍 Gainesville📍 Chicago Novartis Pharmaceuticals · Tests: Secukinumab A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis NCT06869551Phase 348 sites📍 Lancaster📍 Chicago📍 Indianapolis Bristol-Myers Squibb · Tests: Deucravacitinib, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy